• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Inogen Inc

    4/23/24 8:25:34 PM ET
    $INGN
    Industrial Specialties
    Health Care
    Get the next $INGN alert in real time by email
    SC 13G 1 d11036876_13-g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.)*

     

     

    Inogen, Inc.
    (Name of Issuer)

     

     

    Common Stock, $0.001 par value
    (Title of Class of Securities)

     

     

    45780L104
    (CUSIP Number)

     

     

    April 17, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Act or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No. 45780L104    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Divisadero Street Capital Management, LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,388,927  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,388,927  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,388,927  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.9%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

     
     
     

     

    CUSIP No. 45780L104  

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      William Zolezzi  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      U.S.A  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,388,927  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,388,927  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,388,927  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.9%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN, HC

     

     

     

     

     

     
     

     

    CUSIP No. 45780L104  

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Divisadero Street Partners, L.P.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,388,927  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,388,927  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,388,927  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.9%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

     

     

     
     

     

     

     

     

    CUSIP No. 45780L104    

     

         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Divisadero Street Partners GP, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [X]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,388,927  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,388,927  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,388,927  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.9%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    HC, OO

     

     

     
     

     

     

     

    CUSIP No. 45780L104    

     

    Item 1. (a). Name of Issuer:  
           
        Inogen, Inc.  

     

      (b). Address of issuer's principal executive offices:  
           
       

    859 Ward Drive

    Goleta, California 93111

     

     

    Item 2. (a). Name of person filing:  
           
       

    Divisadero Street Capital Management, LP

    Divisadero Street Partners, L.P.

    Divisadero Street Partners GP, LLC

    William Zolezzi

     

    Divisadero Street Capital Management, LP is the investment adviser to private investment funds, including Divisadero Street Partners, L.P., and Divisadero Street Partners GP, LLC is the general partner of Divisadero Street Partners, L.P. William Zolezzi is the control person of Divisadero Street Capital Management, LP and Divisadero Street Partners GP, LLC. Divisadero Street Capital Management, LP, Divisadero Street Partners, L.P., Divisadero Street Partners GP, LLC, and William Zolezzi (collectively, the “Filers”) are filing this statement jointly, but not as members of a group. Each Filer expressly disclaims membership in a group. Each Filer also disclaims beneficial ownership of the Common Stock, $0.001 par value of Inogen, Inc. except to the extent of that Filer’s pecuniary interest therein. The filing of this Schedule 13G on behalf of Divisadero Street Partners, L.P. should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Common Stock, $0.001 par value of Inogen, Inc. covered by this Schedule 13G.

     

     

      (b). Address or principal business office or, if none, residence:  
           
       

    Divisadero Street Capital Management, LP

    3480 Main Highway, Suite 204

    Miami, FL 33133

     

    Divisadero Street Partners, L.P.

    3480 Main Highway, Suite 204

    Miami, FL 33133

     

    Divisadero Street Partners GP, LLC

    3480 Main Highway, Suite 204

    Miami, FL 33133

     

    William Zolezzi

    c/o Divisadero Street Capital Management, LP

    3480 Main Highway, Suite 204

    Miami, FL 33133

     

     

      (c). Citizenship:  
       

     

    Divisadero Street Capital Management, LP – Delaware

    Divisadero Street Partners, L.P. – Delaware

    Divisadero Street Partners GP, LLC – Delaware

    William Zolezzi – United States of America

     

     

      (d).   Title of class of securities:  
           
        Common Stock, $0.001 par value  

      

      (e). CUSIP No.:  
           
        45780L104  

     

     

     

     
     

     

     

     

     

    Item 3.   If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

      (b) [_] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

      (c) [_] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

      (d) [_] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

      (e) [x] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) [x] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

     

      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j)   [_] A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

      (k)   [_] Group, in accordance with §240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
       

    Divisadero Street Capital Management, LP – 1,388,927

    Divisadero Street Partners, L.P. – 1,388,927

    Divisadero Street Partners GP, LLC – 1,388,927

    William Zolezzi – 1,388,927

     

      (b)   Percent of class:
         
       

    Divisadero Street Capital Management, LP – 5.9%

    Divisadero Street Partners, L.P. – 5.9%

    Divisadero Street Partners GP, LLC – 5.9%

    William Zolezzi – 5.9%

     

     
     

     

     

      (c)   Number of shares as to which the person has:
         

     

        (i) Sole power to vote or to direct the vote    
         

    Divisadero Street Capital Management, LP – 0

    Divisadero Street Partners, L.P. – 0

    Divisadero Street Partners GP, LLC – 0

    William Zolezzi – 0

     

     
        (ii)   Shared power to vote or to direct the vote    
         

     

    Divisadero Street Capital Management, LP – 1,388,927

    Divisadero Street Partners, L.P. – 1,388,927

    Divisadero Street Partners GP, LLC – 1,388,927

    William Zolezzi – 1,388,927

     

     
        (iii) Sole power to dispose or to direct the disposition of    
         

     

    Divisadero Street Capital Management, LP – 0

    Divisadero Street Partners, L.P. – 0

    Divisadero Street Partners GP, LLC – 0

    William Zolezzi – 0

     

     
        (iv)   Shared power to dispose or to direct the disposition of    
         

     

    Divisadero Street Capital Management, LP – 1,388,927

    Divisadero Street Partners, L.P. – 1,388,927

    Divisadero Street Partners GP, LLC – 1,388,927

    William Zolezzi – 1,388,927

     

     

      Instruction:  For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).
       
    Item 5. Ownership of Five Percent or Less of a Class.

     

      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
       
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      All securities reported in this Schedule 13G are owned by advisory clients of Divisadero Street Capital Management, LP.  None of the advisory clients individually own more than 5% of the outstanding Common Stock, $0.001 par value of Inogen, Inc.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A
     
     

     

       
    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      April 23, 2024
      (Date)
     

     

    DIVISADERO STREET CAPITAL MANAGEMENT, LP*

       
      By: Divisadero Street Capital LLC, its general partner
       
       
       
      /s/ William Zolezzi
     

    By: William Zolezzi

    Title: Manager

       
      DIVISADERO STREET PARTNERS, L.P*
       
      By: Divisadero Street Partners GP, LLC, its general partner
       
      /s/ William Zolezzi
     

    By: William Zolezzi

    Title: Manager

       
      DIVISADERO STREET PARTNERS GP, LLC*
       
      /s/ William Zolezzi
     

    By: William Zolezzi

    Title: Manager

     

    WILLIAM ZOLEZZI*

     

    /s/ William Zolezzi

     

     

    * The Reporting Persons disclaim beneficial ownership in the Shares reported herein except to the extent of their pecuniary interest therein.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

    Exhibit A

    AGREEMENT

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G and Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Divisadero Street Capital Management, LP, as the undersigned’s true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

      April 23, 2024
      (Date)
     

     

    DIVISADERO STREET CAPITAL MANAGEMENT, LP

       
      By: Divisadero Street Capital LLC, its general partner
       
       
       
      /s/ William Zolezzi
     

    By: William Zolezzi

    Title: Manager

       
      DIVISADERO STREET PARTNERS, L.P
       
      By: Divisadero Street Partners GP, LLC, its general partner
       
      /s/ William Zolezzi
     

    By: William Zolezzi

    Title: Manager

       
      DIVISADERO STREET PARTNERS GP, LLC
       
      /s/ William Zolezzi
     

    By: William Zolezzi

    Title: Manager

       
      WILLIAM ZOLEZZI
       
      /s/ William Zolezzi
       

     

     

     

     

     

     

    Get the next $INGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INGN

    DatePrice TargetRatingAnalyst
    2/15/2024Mkt Perform → Outperform
    William Blair
    8/8/2023$15.00 → $8.00Overweight → Neutral
    JP Morgan
    7/14/2023Buy → Hold
    Needham
    1/17/2023Outperform → Mkt Perform
    William Blair
    12/9/2021$47.00Hold → Buy
    Needham
    11/8/2021$70.00 → $40.00Hold
    Stifel
    11/5/2021$72.00 → $42.00Market Perform
    SVB Leerink
    11/2/2021$71.00 → $45.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $INGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO & Treasurer Bourque Michael J. was granted 48,225 shares, converted options into 25,000 shares, covered exercise/tax liability with 28,579 shares and bought $24,960 worth of shares (3,000 units at $8.32) (SEC Form 4)

      4 - Inogen Inc (0001294133) (Issuer)

      3/4/25 6:42:36 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • CEO and President Smith Kevin Raymond Merrill was granted 55,475 shares, converted options into 28,333 shares, covered exercise/tax liability with 39,797 shares and bought $100,245 worth of shares (11,709 units at $8.56), increasing direct ownership by 383% to 70,274 units (SEC Form 4)

      4 - Inogen Inc (0001294133) (Issuer)

      3/4/25 6:41:11 PM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

      2/3/25 4:00:00 PM ET
      $INGN
      $MDT
      $MYO
      Industrial Specialties
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

      MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con

      11/7/24 4:04:00 PM ET
      $INGN
      $SGHT
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Inogen Appoints Eric Pauls as Vice President of Sales, North America

      Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Eric Pauls as Vice President of Sales, North America, effective September 3, 2024. Mr. Pauls joins Inogen from RQM+, where he served as Chief Customer Officer. Kevin Smith, President and Chief Executive Officer of Inogen said, "We are excited to welcome Eric to the Inogen team. With over 20 years of experience driving growth and leading high-performing teams in the respiratory care business, his leadership will be instrumental as we expand our product offerings and solutions for patients with respiratory conditions in the Uni

      9/5/24 8:30:00 AM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Commercial Officer Ramade Gregoire

      4 - Inogen Inc (0001294133) (Issuer)

      3/4/25 6:44:50 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • EVP, Bus Dev, GC & Sec Smith Kevin P. was granted 1,186 shares (SEC Form 4)

      4 - Inogen Inc (0001294133) (Issuer)

      3/4/25 6:43:26 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • EVP, CFO & Treasurer Bourque Michael J. was granted 48,225 shares, converted options into 25,000 shares, covered exercise/tax liability with 28,579 shares and bought $24,960 worth of shares (3,000 units at $8.32) (SEC Form 4)

      4 - Inogen Inc (0001294133) (Issuer)

      3/4/25 6:42:36 PM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Financials

    Live finance-specific insights

    See more
    • Inogen Announces First Quarter 2025 Financial Results

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2025. "Inogen's strong first quarter financial results underscore our success in driving improved commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "We are making great progress and remain committed to positioning the company for sustainable growth and profitability, while creating value for all stakeholders." First Quarter 2025 Financial Results Total revenue in the first quarter of 2025 was $82.3 million, an increase of 5.5% from the prior-year p

      5/7/25 4:05:00 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen to Report First Quarter 2025 Financial Results on May 7, 2025

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2025 financial results after the market closes on Wednesday, May 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investo

      4/16/25 8:30:00 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen Announces Fourth Quarter and Full Year 2024 Financial Results

      Results Reflect Strong Fourth Quarter 2024 Revenue Growth of 5.5%; Full-Year Revenue Growth of 6.4% Company Provides 2025 Growth Outlook Recently Announced Strategic Collaboration with Yuwell to Expand Product Portfolio, Global Reach Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter and the full year ended December 31, 2024. "2024 was a stellar year for Inogen. With our new leadership team in place, we returned the Company to growth, achieved significant milestones, and made meaningful steps towards profitability," said Kevin Smith, President and Ch

      2/25/25 4:05:00 PM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inogen Announces First Quarter 2025 Financial Results

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2025. "Inogen's strong first quarter financial results underscore our success in driving improved commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "We are making great progress and remain committed to positioning the company for sustainable growth and profitability, while creating value for all stakeholders." First Quarter 2025 Financial Results Total revenue in the first quarter of 2025 was $82.3 million, an increase of 5.5% from the prior-year p

      5/7/25 4:05:00 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen to Report First Quarter 2025 Financial Results on May 7, 2025

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2025 financial results after the market closes on Wednesday, May 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investo

      4/16/25 8:30:00 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen To Present at 24th Annual Needham Virtual Healthcare Conference

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced management will participate in the 24th Annual Needham Virtual Healthcare Conference. Kevin Smith, President and Chief Executive Officer, and Michael Bourque, Chief Financial Officer, are scheduled to participate in a fireside chat on Tuesday, April 8, 2025, at 8:45 a.m. Eastern Time. A live audio webcast and archived recording of the presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. Inogen has used, and intends to continue to use, its Investor Relations website,

      3/20/25 8:30:00 AM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Inogen Inc

      SC 13G/A - Inogen Inc (0001294133) (Subject)

      11/14/24 11:12:09 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Inogen Inc

      SC 13G - Inogen Inc (0001294133) (Subject)

      4/23/24 8:25:34 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Inogen Inc (Amendment)

      SC 13G/A - Inogen Inc (0001294133) (Subject)

      2/14/24 4:00:17 PM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    SEC Filings

    See more
    • Inogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Inogen Inc (0001294133) (Filer)

      5/7/25 4:07:15 PM ET
      $INGN
      Industrial Specialties
      Health Care
    • SEC Form DEFA14A filed by Inogen Inc

      DEFA14A - Inogen Inc (0001294133) (Filer)

      3/27/25 8:03:28 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • SEC Form DEF 14A filed by Inogen Inc

      DEF 14A - Inogen Inc (0001294133) (Filer)

      3/27/25 8:01:55 AM ET
      $INGN
      Industrial Specialties
      Health Care

    $INGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Inogen upgraded by William Blair

      William Blair upgraded Inogen from Mkt Perform to Outperform

      2/15/24 6:28:38 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen downgraded by JP Morgan with a new price target

      JP Morgan downgraded Inogen from Overweight to Neutral and set a new price target of $8.00 from $15.00 previously

      8/8/23 6:37:35 AM ET
      $INGN
      Industrial Specialties
      Health Care
    • Inogen downgraded by Needham

      Needham downgraded Inogen from Buy to Hold

      7/14/23 7:51:45 AM ET
      $INGN
      Industrial Specialties
      Health Care